You are here: Home » Companies » News
Business Standard

Glenmark gets FDA approval for nasal spray for seasonal allergic rhinitis

Glenmark Pharmaceuticals Limited said its subsidiary Glenmark Specialty S.A. has received US FDA approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris.

Glenmark Pharmaceuticals | US FDA

IANS  |  Chennai 


Pharma major Limited on Friday said its fully owned Swiss subsidiary Glenmark Specialty S.A. has received the US Food and Drug Administration's (FDA) approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris.

According to Glenmark, the drug is for rhinitis in adults and paediatric patients 12 years of age and older in the US.

"The FDA's approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas." said Chief Commercial Officer Robert Crockart.

Ryaltris will be marketed and distributed in America by Hikma Specialty U.S.A., Inc., as part of its exclusive licensing agreement with Glenmark Specialty S.A.

Glenmark has entered into commercial agreements with several partners around the world, including Menarini for the commercialisation of Ryaltris in select EU markets, and with Bausch Health in Canada (where it is under review by Health Canada), the company said.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 14 2022. 15:48 IST